216 related articles for article (PubMed ID: 37941347)
21. Laboratory Discrimination Between Neutrophilic Malignant and Parapneumonic Pleural Effusions.
Lee J; Lee YH; Seo H; Lee H; Kim YK; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
Am J Med Sci; 2019 Aug; 358(2):115-120. PubMed ID: 31331448
[TBL] [Abstract][Full Text] [Related]
22. Differences in
Xie T; Wang Q; Gao J; He K; Yu J
Ann Clin Lab Sci; 2024 Mar; 54(2):201-210. PubMed ID: 38802158
[TBL] [Abstract][Full Text] [Related]
23. Auxiliary diagnostic value of tumor biomarkers in pleural fluid for lung cancer-associated malignant pleural effusion.
Zhang H; Li C; Hu F; Zhang X; Shen Y; Chen Y; Li F
Respir Res; 2020 Oct; 21(1):284. PubMed ID: 33121490
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in malignant pleural effusion in patients with lung cancer.
Xu CH; Hao KK; Yu LK; Zhang XW
Asia Pac J Clin Oncol; 2015 Mar; 11(1):28-33. PubMed ID: 24720371
[TBL] [Abstract][Full Text] [Related]
25. The diagnostic value of pleural fluid homocysteine in malignant pleural effusion.
Santotoribio JD; Del Valle-Vazquez L; García-de la Torre A; Del Castillo-Otero D; Lopez-Saez JB; Sanchez Del Pino MJ
PLoS One; 2019; 14(9):e0222616. PubMed ID: 31550262
[TBL] [Abstract][Full Text] [Related]
26. Idiopathic Pleural Effusions: Characteristics and Discrimination From Cytology-Negative Malignant Pleural Effusions.
Park JE; Do YW; Lee DH; Lee SY; Lim JK; Choi SH; Seo HW; Yoo SS; Lee SY; Cha SI; Park JY; Lee J; Kim CH
Am J Med Sci; 2020 Sep; 360(3):236-242. PubMed ID: 32423747
[TBL] [Abstract][Full Text] [Related]
27. Cell-free DNA methylation analysis as a marker of malignancy in pleural fluid.
Bixby B; Vrba L; Lenka J; Oshiro MM; Watts GS; Hughes T; Erickson H; Chopra M; Knepler JL; Knox KS; Jarnagin L; Alalawi R; Kala M; Bernert R; Routh J; Roe DJ; Garland LL; Futscher BW; Nelson MA
Sci Rep; 2024 Feb; 14(1):2939. PubMed ID: 38316884
[TBL] [Abstract][Full Text] [Related]
28. Diagnosing malignant pleural effusion using clinical and analytical parameters.
Pan Y; Bai W; Chen J; Mao Y; Qian X; Xu K; Tang S; Zhang J; Chen C; Chen J; Hu X
J Clin Lab Anal; 2019 Feb; 33(2):e22689. PubMed ID: 30390322
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic accuracy of endostatin for malignant pleural effusion: A clinical study and meta-analysis.
Tian P; Shen Y; Feng M; Zhu J; Song H; Wan C; Chen L; Wen F
Postgrad Med; 2015 Jun; 127(5):529-34. PubMed ID: 25979108
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion.
Han HS; Yun J; Lim SN; Han JH; Lee KH; Kim ST; Kang MH; Son SM; Lee YM; Choi SY; Yun SJ; Kim WJ; Lee OJ
Int J Cancer; 2013 Aug; 133(3):645-52. PubMed ID: 23354517
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic accuracy of tumor markers for malignant pleural effusion: a derivation and validation study.
Zhai K; Wang W; Wang Y; Liu JY; Zhou Q; Shi HZ
J Thorac Dis; 2017 Dec; 9(12):5220-5229. PubMed ID: 29312729
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of pleural interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions.
Xu CH; Zhan P; Yu LK; Zhang XW
Tumour Biol; 2014 Feb; 35(2):1599-603. PubMed ID: 24072496
[TBL] [Abstract][Full Text] [Related]
33. [Evaluation of the diagnosis value of carcinoembryonic antigen in malignant pleural effusion].
Yu YX; Tong ZH; Zhou XX; Liang LR; Wang Z; Xu LL; Wang XJ; Wu YB; Li HJ; Lu Z
Zhonghua Yi Xue Za Zhi; 2018 Feb; 98(6):432-435. PubMed ID: 29429254
[No Abstract] [Full Text] [Related]
34. Study on the application of percutaneous closed pleural brushing combined with cell block technique in the diagnosis of malignant pleural effusion.
Wang K; Hu X; Chen Y; Yi X; Han X; Zhu D; Zhu B; Luo H
Clin Respir J; 2024 Jan; 18(1):e13705. PubMed ID: 37775991
[TBL] [Abstract][Full Text] [Related]
35. Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion.
Lee J; Lee DH; Park JE; Lee YH; Choi SH; Seo H; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
Korean J Intern Med; 2024 Mar; 39(2):318-326. PubMed ID: 38351680
[TBL] [Abstract][Full Text] [Related]
36. Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion.
Botana-Rial M; Casado-Rey P; Leiro-Fernández V; Andrade-Olivié M; Represas-Represas C; Fernández-Villar A
Clin Lab; 2011; 57(5-6):373-8. PubMed ID: 21755828
[TBL] [Abstract][Full Text] [Related]
37. Combination of long noncoding RNA
Wang WW; Zhou XL; Song YJ; Yu CH; Zhu WG; Tong YS
Onco Targets Ther; 2018; 11():2333-2344. PubMed ID: 29731641
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic value of pleural effusion Krebs von den Lungen-6 in malignant pleural effusion of patients with non-small cell lung cancer.
Wang J; Ling L; Chen S; Chou L; Wang Y; Hu L
Lab Med; 2024 May; 55(3):271-276. PubMed ID: 37566516
[TBL] [Abstract][Full Text] [Related]
39. Pleural IFN-γ release assay combined with biomarkers distinguished effectively tuberculosis from malignant pleural effusion.
Tang Y; Zhang J; Huang H; He X; Zhang J; Ou M; Li G; Zeng C; Ye T; Ren L; Liu Y; Zhang G
BMC Infect Dis; 2019 Jan; 19(1):55. PubMed ID: 30651075
[TBL] [Abstract][Full Text] [Related]
40. A novel diagnostic method for distinguishing parapneumonic effusion and empyema from other diseases by using the pleural lactate dehydrogenase to adenosine deaminase ratio and carcinoembryonic antigen levels.
Saraya T; Ohkuma K; Koide T; Goto H; Takizawa H; Light RW
Medicine (Baltimore); 2019 Mar; 98(13):e15003. PubMed ID: 30921217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
